Startup Advisory

Physician-led clinical customer discovery advisory for pre-seed to Series B healthtech and medtech founders.

Review your interview guide from a clinician perspective. Get warm introductions to physiatrists, rehab directors, and hospital operations leadership. Interview coaching. Synthesis. Flat-fee tiers from $2,500.

Or book a free 20-minute scoping call →
Physician-led advisory Flat-fee tiers Founder coaching Warm clinical introductions
8+ years clinical operations + physician-executive background
45+ KOL engagements at AbbVie (MSL neurology)
90+ healthtech and medtech founder conversations
30+ hospital/health system operational advisory engagements
100% founder-led responses, no auto-reply funnel
NewsHX Healthcare Intelligence Current . May 2026

What is moving in digital health and health tech right now.

Three signals from current market activity. Each one shapes the competitive and funding landscape for health tech founders.

Big Tech Health

Amazon restructures health services leadership — signals renewed push into clinical care delivery, not just logistics and pharmacy

Amazon named the former Amwell co-founder as head of health services. The move signals Amazon is doubling down on clinical service delivery, not stepping back. For digital health startups, this reshapes the competitive landscape and the partnership calculus with platform-scale distribution.

Healthcare Dive May 28, 2026
Platform Consolidation

Teladoc deploys clinical services inside Walmart's virtual health hub — digital health distribution consolidates around retail platforms

Teladoc virtual urgent care, dermatology, and nutrition now live inside Walmart's Better Care Services. The move compresses the distribution layer for point solutions. Startups building standalone virtual care need a platform story or a differentiated clinical niche to avoid being absorbed.

Modern Healthcare May 28, 2026
Capital Activity

PE capital accelerates acquisitions of existing home-based care operators as new enrollment stays frozen under the CMS moratorium

Monroe Capital backed a Warburg Pincus investment in Cornerstone Caregiving as the CMS moratorium freezes new entrants. Capital that used to fund new licenses is flowing to acquisitions of existing operators. For health tech startups building for home-based care, the buyer landscape is institutional — not just operator.

Home Health Care News May 28, 2026
Source: NewsHX Healthcare Intelligence newshx.com Digital Health and Health Tech Feed
What we actually do . § 02

Four lanes. Flat fee. No equity.

Lane 01 Tier 01 . $2,500

Clinical Customer Discovery Sprint

Interview guide review, 3 warm clinical introductions, 1 coaching session.

Lane 02 Tier 02 . $7,500

Discovery Package

Everything in Tier 01 plus synthesis memo, 5 warm intros, 2 follow-on sessions.

Lane 03 $3,500/month

Ongoing Clinical Advisor

Retained monthly. Interview prep, synthesis, KOL strategy, pitch review, clinical landscape updates.

Lane 04 Custom

Full Clinical + Market Access

For Series A/B. Clinical strategy plus life sciences pathway mapping, payer landscape, reimbursement framing, regulatory navigation.

A different fit

If your problem is below, another partner will serve you better.

  • Post-clearance medtech commercialization Better served by our /life-sciences vertical.
  • Equity-only fractional CMO We do not take equity. An executive-search firm is a better fit.
  • Consumer DTC health products A consumer-health growth advisor will move faster than we will.
  • Adjacent needs Email us. If we are not the right fit we will say so, often within 24 hours.
Ecosystem . § 09

The A3HCS ecosystem. One philosophy, four arms.

A3HCS sits at the center of a small ecosystem of related entities. Each has a distinct audience and economic model. Brain Revives is the patient and caregiver education arm, related but not the primary commercial path.

A purpose-built bridge from the system to the kitchen table.

Brain Revives is a patient and caregiver education platform for traumatic brain injury, stroke, and acquired brain injury recovery. When an A3HCS engagement touches the home, complex discharge, or post-acute caregiver activation, Brain Revives provides the education infrastructure most health systems do not have time to build internally. Brain Revives is education, not clinical care delivery.

Buyers engage A3HCS directly. Patients and caregivers engage Brain Revives. The arms share a clinical philosophy and a continuity discipline, but distinct audiences and economics.

A separate brand . Same clinical philosophy Visit Brain Revives →
A³HCS Advisory Hub Buyer-facing strategy
DOMD Healthcare Execution Arm Operations & consulting
A3HCS Liaison Transition Arm Care transition liaison
Brain Revives Education Arm Patient & caregiver
Life Sciences Market Access Drug . Device . Health Tech

One philosophy across four arms . distinct audiences

Common Questions

What you might be wondering.

What does a clinical customer discovery advisor actually do for a healthtech startup?

Reviews your interview guide, opens warm clinical introductions, coaches you through the calls, and synthesizes findings into a written memo. The work happens before you have product strategy conviction. The output is whether the clinical need you imagined matches the one clinicians actually live with.

How is this different from a part-time clinical advisor or a chief medical officer?

A clinical advisor lends a name and shows up monthly. A CMO is a year-plus commitment with equity. We are productized. Tier 01 is $2,500 and starts inside a week. You buy the work, not the relationship. If the work compounds we go deeper. If it does not we both move on without overhang.

How much does clinical customer discovery advisory cost?

Tier 01 Discovery Sprint at $2,500. Tier 02 Discovery Package at $7,500. Ongoing Clinical Advisor at $3,500 per month. Full Clinical + Market Access at custom scope. All flat fees, no equity, no retainer minimums beyond what is stated.

What stage of health tech startup benefits most from clinical customer discovery?

Pre-seed through Series A. At pre-seed, discovery determines whether the clinical problem you are solving is real and urgent. At seed and Series A, it validates that your solution fits the workflow of the buyer you are selling to. After Series A, the clinical narrative is usually set — the work shifts to KOL engagement and market access, which is a different engagement.

Does A3HCS take equity or advisory shares in startups?

No. A3HCS does not take equity, advisory shares, or any form of deferred compensation. All engagements are flat fee, paid at engagement start. This keeps the advice independent — the recommendation is what the data shows, not what benefits an equity position.

How many warm clinical introductions are included at each tier?

Tier 01 includes three warm clinical introductions. Tier 02 includes five. Ongoing Clinical Advisor includes ongoing introductions as the relationship develops. Introductions are to physicians and clinical leaders in the relevant specialty and care setting — not cold LinkedIn messages. They are based on existing relationships, and A3HCS briefs the contact before making the introduction.

What clinical specialties and care settings does A3HCS have introductions in?

Primary care, hospital medicine, neurology, psychiatry, emergency medicine, care transitions and discharge planning, post-acute and home health, and health system operations leadership. Strongest network is in Midwest health systems and physician groups. Introductions outside that geography are evaluated case by case.

How long does a clinical customer discovery sprint take?

Tier 01 Discovery Sprint runs two weeks from kickoff. Tier 02 Discovery Package runs four weeks. The Ongoing Clinical Advisor retainer runs monthly with no fixed end date. All timelines start from the day the engagement is confirmed — not from when the contract is signed.

Primary CTA . § 12

Request a Care Transition and Growth Diagnostic.

A two-to-four-week structured diagnostic delivered as an executive memo, not a deck. It defines where your system is losing time, margin, and trust, and identifies the two-to-three corrections worth investing in next.

  • Structured interviews with operational and clinical owners
  • Data pull and variance analysis against peer benchmarks
  • System map of friction points across the continuum
  • Executive memo with prioritized correction paths
  • No findings before facts. No outcome guarantees. Clear scope.